Patient or Caregiver >

If you're a patient on PROCRIT®
it's important you talk to your physician. New safety information has been released that you should be aware of. For further information please click here

Healthcare Professional >

If you're a physician prescribing PROCRIT there is new safety information that could affect your patients. For safety information, full prescribing information, including Boxed WARNINGS and FDA alerts, please click here

VOLUNTARY PRODUCT WITHDRAWAL NOTICE
Click here to read about important information regarding PROCRIT® (Epoetin alfa).

Contact Us >

WARNINGS:  INCREASED MORTALITY, SERIOUS CARDIOVASCULAR AND THROMBOEMBOLIC EVENTS, AND TUMOR PROGRESSION

Renal failure:  Patients experienced greater risks for death and serious cardiovascular events when administered erythropoiesis-stimulating agents (ESAs) to target higher versus lower hemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in two clinical studies. Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.  

Cancer:
  • ESAs shortened overall survival and/or time-to-tumor progression in clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers when dosed to target a hemoglobin of ≥ 12 g/dL.
  • The risks of shortened survival and tumor progression have not been excluded when ESAs are dosed to target a hemoglobin of < 12 g/dL.
  • To minimize these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusions.
  • Use only for treatment of anemia due to concomitant myelosuppressive chemotherapy.
  • Discontinue following the completion of a chemotherapy course.

Perisurgery:  PROCRIT® increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation.  Consider deep venous thrombosis prophylaxis.

(See WARNINGS:  Increased Mortality, Serious Cardiovascular and Thromboembolic Events, WARNINGS:  Increased Mortality and/or Tumor Progression, and DOSAGE AND ADMINISTRATION.)

           Please see Full Prescribing Information, including Boxed WARNINGS for more details.

By using this site, you agree to our Legal Notice and Privacy Policy. This site is published by Ortho Biotech Products, L.P. which is solely responsible for its contents. It is intended for visitors from the United States. ©2002-2007 Ortho Biotech Products, LP.